Argent Capital Management LLC Has $1.07 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Argent Capital Management LLC decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 5.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,200 shares of the medical research company’s stock after selling 856 shares during the period. Argent Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,069,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at about $28,000. First Community Trust NA bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $29,000. Riverview Trust Co bought a new stake in Edwards Lifesciences in the first quarter valued at $34,000. Webster Bank N. A. bought a new position in shares of Edwards Lifesciences in the second quarter valued at $39,000. Finally, Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock valued at $1,099,238 in the last ninety days. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

EW has been the subject of several research reports. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. Citigroup decreased their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, October 1st. Finally, Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Fifteen investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $75.81.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.56 on Thursday, reaching $71.17. The company’s stock had a trading volume of 1,643,064 shares, compared to its average volume of 4,553,102. The company has a market capitalization of $42.89 billion, a price-to-earnings ratio of 30.44, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The stock’s fifty day simple moving average is $68.04 and its 200-day simple moving average is $78.71. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the previous year, the firm posted $0.66 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.